When was TScan Therapeutics founded?

TScan Therapeutics was founded in 1995 and raised its 1st funding round 24 years after it was founded.

Where is TScan Therapeutics located?

TScan Therapeutics is headquartered in Boston, United States. It is registered at Waltham, Massachusetts.

Who is the current CEO of TScan Therapeutics?

David P. Southwell of TScan Therapeutics.

How many employees does TScan Therapeutics have?

As of May 31, 2026, the latest employee count at TScan Therapeutics is 148.

Is TScan Therapeutics a funded company?

TScan Therapeutics is a funded company, having raised a total of $180M across 3 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Jul 24, 2019.

When was the latest funding round of TScan Therapeutics?

TScan Therapeutics' latest funding was a $***** Series C round on Jan 25, 2021, with participation from 8 investors.

What is the annual revenue of TScan Therapeutics?

Annual revenue of TScan Therapeutics is between $10M and $50M as on Dec 31, 2025

Where does TScan Therapeutics rank among its competitors?

TScan Therapeutics ranks 4th amongst 836 active competitors, of which 342 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of TScan Therapeutics?

TScan Therapeutics' top competitors include Abcellera Biologics, Immuneel and Agios Pharmaceuticals. Among them, Immuneel secured the most recent funding round in June, 2026.

TScan Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of T cell therapies to harness the immune system against cancer. The company focuses on hematologic malignancies and solid tumors using proprietary platforms like TargetScan and ReceptorScan. The company's product line include TSC-100 and TSC-101 target residual disease in AML, MDS, and ALL patients post-allogeneic hematopoietic cell transplant.

Website: www.tscan.com/
Social
Email ID: *****@tscanrx.com
Registered Address: Waltham, Massachusetts

Key Metrics

Founded Year

1995

Location

Boston, United States

Stage

Public

Total Funding

$180M in 3 rounds

Latest Funding Round

Series C, Jan 25, 2021, $*****

Investors

Pitango & 10 more

Ranked

4^th among 836 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2025

Employee Count

148 as on May 31, 2026

Similar Companies

Abcellera Biologics & 984 more

Exit Details

Public

View TScan Therapeutics' full profile

TScan Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Tscan Therapeutics, Inc. CIN: 82-5282075 , United States, Active	Apr 16, 2018	$10M - $50M (As on Dec 31, 2025)	154 (As on Dec 31, 2023)	-
TSCAN THERAPEUTICS INC. CIN: 825282075 , United States, Active	Dec 26, 999	-	188 (As on Dec 31, 2024)	-

TScan Therapeutics got listed on Jul 16, 2021.

Click here to take a look at TScan Therapeutics's IPO in detail

TScan Therapeutics has raised a total funding of $180M over 3 rounds. Its first funding round was on Jul 24, 2019. Its latest funding round was a Series C round on Jan 25, 2021 for $*****. 8 investors participated in its latest round. TScan Therapeutics has 11 institutional investors.

Here is the list of recent funding rounds of TScan Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 25, 2021	6283289	Series C	4385827	4943847	4314475	2651127
Jan 09, 2020	3944360	Series B	9680876	5386194	9949949	Novartis & 4 more
Jul 24, 2019	7543133	Series B	5958771	3987570	Novartis	Google Ventures & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of TScan Therapeutics's funding rounds and investors

The founders of TScan Therapeutics is Lea Hachigian.

Here are the details of TScan Therapeutics' key team members:

Lea Hachigian: Co-Founder & President of TScan Therapeutics and founder of 1 other company.
David P. Southwell: CEO of TScan Therapeutics.

View details of TScan Therapeutics's Founder profiles and Board Members

TScan Therapeutics' employee count trend

TScan Therapeutics has 148 employees as of May 26. Here is TScan Therapeutics's employee count trend over the years:

Employee count trend for TScan Therapeutics

Uncover TScan Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of TScan Therapeutics include Abcellera Biologics, Immuneel and Agios Pharmaceuticals. Here is the list of Top 10 competitors of TScan Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	76/100
2nd	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Eight Roads Ventures & 23 others	71/100
3rd	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Flagship Pioneering, Arch Venture Partners ... & 6 others	70/100
4th	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	Google Ventures, RA Capital Management & 9 others	70/100
5th	ImmunoACT 2018, Mumbai (India), Series B	Developer of cell and gene therapies for cancer treatment	$15.9M	SINE, Laurus Labs & 4 others	69/100
6th	Viridian Therapeutics 2007, Boulder (United States), Public	Developer of medicines for patients with serious and rare diseases	$14.5M	Fairmount Funds Management, Longitude Capital ... & 2 others	69/100
7th	Achilles Therapeutics 2016, London (United Kingdom), Public	Developer of T-cell therapies for cancer	$242M	Boxer Capital, RA Capital Management & 41 others	68/100
8th	Dren Bio 2019, San Carlos (United States), Series B	Developer of therapeutic antibodies for the treatment of cancer, autoimmune, and other serious diseases	$156M	Aisling Capital, HBM Healthcare Investments ... & 13 others	68/100
9th	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	68/100
10th	Aurinia Pharmaceuticals 1993, Edmonton (Canada), Public	Developer of therapeutics for autoimmune diseases	-	VenBio, RA Capital Management & 10 others	67/100